Navigation Links
Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy
Date:1/4/2012

olio at Genzyme and founding multiple life science and healthcare companies. 

"We are in a race against time to find safe and effective therapies for boys with DMD," said Benjamin Seckler, MD, President of Charley's Fund. "Our partnering with Nash Avery Foundation to establish Halo Therapeutics is the next step in the DMD patient community's tireless effort to find such a therapy. We're excited to have Gene and Marc, experienced drug development and biopharma industry business professionals, leading the company."

HT-100 works by inhibiting the pathological fibrotic process in muscle and directly stimulating healthy muscle fiber regeneration. The company has acquired an extensive data package on HT-100 including results of numerous animal model studies, a comprehensive toxicology package, and human clinical data from multiple trials in healthy volunteers and select disease populations.

Planning is well underway for clinical evaluation of the compound. CEO Marc Blaustein said, "We're extremely pleased that HT-100 has received orphan drug designation. This adds momentum to the significant progress we've made since our founding, and we are pressing forward to initiate a Phase II clinical trial in 2012 to evaluate HT-100 in DMD patients."About Duchenne Muscular DystrophyDuchenne muscular dystrophy is caused by a mutation in the dystrophin gene, resulting in progressive muscle weakness. The disease manifests itself first in weakened skeletal muscles and eventually results in cardiac and pulmonary impairment. Corticosteroids are the current standard of care treatment for DMD.  While this treatment delays disease progression by several years, their prolonged use is typically associated with side effects and the treatment does not alter the ultimate outcome of the disease. Young men with Duchenne typically live into their twenties or early thirties.

About Halo TherapeuticsBased in Newton, Mass., Halo Therapeutics, LLC, is a clinical
'/>"/>

SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics Announces $3.6 Million Warrant Exercises
2. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
3. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
4. AuraSense Therapeutics Secures Series B Equity Investment
5. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
6. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
7. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
8. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
9. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
10. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
11. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... Fair Trading (OFT) approval condition to the announced tender offer for ... As a result of the waiver, the transaction is ... the tender offer on January 24, 2014 following the currently scheduled ...
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb ... in ambulances and other transport vehicles, an advanced and portable UV ... personnel for the first time. In order to ... these deadly pathogens, West Palm Beach Fire ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... the first time, researchers have access to detailed information ... health care. A new study, called Our Health Counts, ... challenges faced by urban Aboriginal people in Canada ... The findings, published today in BMJ Open , ... the general population. , Researchers interviewed 554 First Nations ...
(Date:7/9/2014)... After Susan Wakulich was told she had an aneurysm, she ... of her. , "I was devastated," said Wakulich, who is ... knew this was a serious diagnosis. Then I met Dr. ... involved a less invasive procedure. It was something I didn,t ... in a multi-center U.S. clinical trial to evaluate the safety ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Urban Aboriginal people face unique health challenges 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2
... all set to start its manufacturing facility in ... Japanese drug market. ,Ind-Swift Laboratories has ... for its Clarithromycin active pharmaceutical ingredient (API) manufacturing ... Thursday. ,Clarithromycin is a macrolide antibiotic ...
... Singh (SMS) medical college here will set up a stem ... genetics// and stem cells. ,The laboratory, to be ... the state government-run institute, has been taken up under an ... and technology. ,Ashok Pangariya, principal of the SMS ...
... has been urged to redouble its efforts in the fight against ... Joint United Nations program on HIV/AIDS, comes after Fiji's Ministry of ... living with HIV and AIDS, reported Fijilive Thursday. ,The ... to 25 in 2005 and four cases in 1996. ...
... Seven industrialized nations on Friday plans to sign an ... //diseases - including HIV/AIDS, TB //and malaria - that ... on Tuesday. ,Under the program, donor ... developed at a preferential price when they are available. ...
... Technion-Israel Institute of Technology have figured out a way ... into a guided missile that strikes specifically at a ... ,Professor Amram Mor of the Biotechnology and ... peptide, a small molecule made of short chains of ...
... Drug Administration has approved the sale of a diet drug which can ... which was previously sold as a prescription drug by the name Xenical ... be sold in 60 mg capsules while Xenical was sold in 120 ... it is said to be very effective. The price is expected to ...
Cached Medicine News:Health News:Stem Cell Research Lab Coming Up in Jaipur 2Health News:Bacteria Fighter Goes Where Antibiotics Can't 2
... The Sysmex pocH-100i is the first Sysmex ... low daily testing requirements. With its small ... differential from just 15 L of whole ... any small healthcare site including the emergency ...
... a self-contained, compact, easy-to-use, bedside automated cell ... Ichor system provides a hematology profile of ... platelet aggregation within five minutes. The test ... is added to both an EDTA baseline ...
... pacemaker family, which includes the world's ... the most advanced pacemaker technology available, ... the first and only U.S. commercially ... fibrillation (AF). The AF Suppression algorithm ...
... catheters that are controlled by an ... console processes the refrigerant, which when ... the catheter, creates cryogenic temperatures., ,The ... touch-screen interface. From this interface, the ...
Medicine Products: